510(k) Report

510(k) · Cleared

Cleared

Luminopia

K233720510(k) TraditionalCleared Aug 8, 2024261-day reviewClass II21 CFR 886.5500

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Luminopia, Inc. · QQU Digital Therapy Device For Amblyopia

Cleared on Aug 8, 2024 as substantially equivalent to K221659 (Luminopia, Inc., 2022) after a 261-day review. Its family tree reaches back 2 generations to 2021. 1 later device descends from it.

Decided
Aug 8, 2024
Review
261 days
Class
Class II
Product code
QQU
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to DEN210005 (2021). 1 later device descends from it, 1 citing it directly.

Descendants, by year cleared 2025: 1 descendant clearedDEN210005 · Luminopia One · Luminopia, Inc. · 2021K221659 · Luminopia One · Luminopia, Inc. · 20222020202220242026
Descendants, by generation 1 generation forward: 1 descendant K221659 · Luminopia One · Luminopia, Inc. · 2022DEN210005 · Luminopia One · Luminopia, Inc. · 20210
  1. Root · 2 generations backDEN210005 Luminopia OneLuminopia, Inc. · 2021
  2. 1 generation backK221659 Luminopia OneLuminopia, Inc. · 2022
  3. This deviceK233720 LuminopiaLuminopia, Inc. · 2024
  4. Descendant · cites it directly · 0 of its ownK243819 LuminopiaLuminopia, Inc. · 2025

Most influential descendants

Showing 1 of 1 · See all
  • K243819LuminopiaLuminopia, Inc. · 2025 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2DEN210005Luminopia OneLuminopia, Inc.2021—
−1K221659Luminopia OneLuminopia, Inc.2022—
0 (this device)K233720LuminopiaLuminopia, Inc.2024—
+1K243819LuminopiaLuminopia, Inc.2025—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
202510
FIG. 1 — Lineage of K233720, 2021–2025Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in QQU? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new QQU device

  1. #1 K243819 Luminopiascore 9.7 · 3 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K221659Luminopia One
Summary page 5
…pia” Common Name: N/A Classification Name: Digital Therapy Device for Amblyopia (21 CFR 886.5500, Product Code: QQU) Predicate Device: Luminopia One (Submission Number: K221659) Indications for Use: Luminopia is a software-only digital therapeutic designed to be used with commercially available Head-Moun…
Luminopia, Inc.2022—

What descends from it? (1)

1 later device cites it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K243819LuminopiaLuminopia, Inc.20250

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 3 years and passes through 1 company; a new generation was cleared every 1.8 years on median.
  • None of the 2 ancestors has a recall.
  • Of its descendants, K243819 (Luminopia, Inc., 2025) has gone furthest, with 0 descendants of its own.

How does its category compare?

All QQU devices

QQU Digital Therapy Device For Amblyopia: FDA decisions, review times, recalls and adverse event reports over 20 years. 2024, this device’s year, is highlighted.

FDA decisions per year · QQU

1in 2025

2021: 12022: 22024: 12025: 1
2007high 2 (2022) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · QQU

Too few QQU 510(k)s in any year since 2007 to give a median.

Recalls per year · QQU

No recall names QQU since 2007.

Adverse event reports per year · QQU

1in 2025

2025: 1
2007high 1 (2025) · low 0 (2007)2025

MAUDE reports naming product code QQU, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20180—00
20190—00
20200—00
20211—00
20222—00
20230—00
20241—00
20251—01
20260—0—

What is it indicated for?

Luminopia is a software-only digital therapeutic designed to be used with commercially available Head-Mounted Displays (HMDs) which are compatible with the software application. Luminopia is indicated for improvement in visual acuity in amblyopia patients, aged 4-7, associated with anisometropia and/or with mild strabismus, having received treatment instructions (frequency and duration) as prescribed by a trained eye-care professional. Luminopia is…

Read the full statement (123 words)

Luminopia is a software-only digital therapeutic designed to be used with commercially available Head-Mounted Displays (HMDs) which are compatible with the software application. Luminopia is indicated for improvement in visual acuity in amblyopia patients, aged 4-7, associated with anisometropia and/or with mild strabismus, having received treatment instructions (frequency and duration) as prescribed by a trained eye-care professional. Luminopia is intended for both previously treated and untreated patients; however, patients with more than 12 months of prior treatment (other than refractive correction) have not been studied. Luminopia is intended to be used as an adjunct to full-time refractive correction, such as glasses, which should also be worn under the HMD during Luminopia therapy. Luminopia is intended for prescription use only, in an at-home environment.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K233720: Luminopia.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K233720

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026